Tatsuyuki Chiyoda

Keio University School of Medicine
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (23)

AGR2-knockout (KO) in AGR2-low clear cell ovarian cancer (CCC) did not suppress cell growth A, Immunoblot analysis confirmed AGR2 KO. B, AGR2 KO did not suppress cell growth in AGR2-low CCC organoid (18-015).

Year:

2025

QIAGEN Ingenuity Pathway Analysis results for unfolded protein response, filtered by DESeq2 analysis of AGR2 KO vs. control with abs(logFC) of >1.5 (p

Year:

2025

Cdk1/2/5/9 gene expression differences between dinaciclib-resistant CCC organoids (19-055, 19-076, and 19-079) vs. the dinaciclib-sensitive CCC organoids (180-015, 19-001, 19-010, 19-042, 19-044, 18-148). A log fold change (logFC) greater than 0 was considered to indicate higher gene expression in dinaciclib-resistant samples.

Year:

2025

Box plot showing Single-sample Gene Set Enrichment Analysis (ssGSEA) scores significantly different between AGR2-knockout organoids and controls (HALLMARK_WNT_BETA_CATENIN_SIGNALING, HALLMARK_P53_PATHWAY, HALLMARK_PEROXISOME, HALLMARK_EPITHELIAL_MESENYCHYMAL_TRANSITION, HALLMARK_NOTCH_SIGNALING, HALLMARK_COAGULATION, HALLMARK_PROTEIN_SECRETION, HALLMARK_HYPOXIA). CCC, clear cell ovarian cancer; cont., control; HGSC, high-grade serous ovarian cancer

Year:

2025

QIAGEN Ingenuity Pathway Analysis results for unfolded protein response, filtered by DESeq2 analysis of AGR2 KO vs. control with abs(logFC) of >1.5 (p

Year:

2025

The activation of the UPR in CCC, with a higher level of activation observed following treatment with bortezomib. A, GSEA of the IRE1α pathway, PERK pathway, and ATF6 pathway in CCC, multiple myeloma from TCGA, and normal ovary from the Genotype-Tissue Expression database. B, PCA of ssGSEA using ATF6, IRE1α, and PERK pathways. TCGA-OV, TCGA ovarian cancer; TCGA-PAAD, TCGA pancreatic adenocarcinoma. C, Bright-field image of CCC organoid (19-042) treated with bortezomib (50 nmol/L, 24 hours) or dinaciclib (500 nmol/L, 24 hours). D, Immunoblot analysis of UPR markers (IRE1α, XBP1s, PERK, and ATF6) and an apoptosis marker (cleaved caspase-3) following treatment with bortezomib (10 or 50 nmol/L, 24 hours) or dinaciclib (100 or 500 nmol/L, 24 hours). E, TEM images after treatment with bortezomib (50 nmol/L, 24 hours) or dinaciclib (500 nmol/L, 24 hours). The arrowhead indicates the ER. Bortezomib treatment at 50 nmol/L significantly induced ER lumen dilatation ( P

Year:

2025

HTDS for CCC organoids using a 384-well plate. A, ATP luminescence-based HTDS system. B, Two independent HTDS showed reproducible results in two CCC organoids. C, Schematic presentation of HTDS with 361 compounds for six CCC organoids. HTDS identified 17 compounds with inhibition efficiencies over 70%. D, Dose–response curve of eight compounds for nine CCC organoids. The IC 50 of each compound in each organoid is shown.

Year:

2025

There are currently no effective treatments available for clear cell ovarian cancer (CCC). In this study, we aimed to identify effective drugs for CCC through high-throughput drug screening (HTDS) using ovarian cancer organoids and determine novel therapeutic targets based on the biological characteristics of CCC through omics analysis. An ovarian cancer organoid biobank was established, and HTDS was conducted using CCC organoids based on libraries of 361 and 4,560 compounds. The efficacy of the identified drugs was verified in in vitro and in vivo experiments using a patient-derived organoid xenograft mouse model. Transcriptome analysis was performed to identify genes related to the pathways targeted by the identified drugs in CCC and to assess their potential as therapeutic targets. Proteasome inhibitors and dinaciclib were extracted using HTDS and shown to inhibit tumorigenesis in vitro and in vivo . CCC, like multiple myeloma, exhibited activated endoplasmic reticulum (ER) stress and unfolded protein response (UPR), and treatment with proteasome inhibitors further enhanced ER stress and UPR, ultimately leading to cell death. Transcriptome analysis identified anterior gradient-2 ( AGR2 ) as a key gene involved in UPR in CCC. CRISPR knockout of AGR2 suppressed cell proliferation, increased sensitivity to proteasome inhibitors, and reversed platinum resistance in CCC. AGR2 knockout also upregulated Schlafen 11 , contributing to platinum sensitivity. ER stress and the UPR are activated in CCC, and proteasome inhibitors disrupt this balance, ultimately leading to cell death. AGR2 may serve as a potential therapeutic target in CCC. Significance: Proteasome inhibitors and dinaciclib are identified as effective drugs for CCC. CCC has a high basal UPR, and proteasome inhibition may disrupt this balance. AGR2 is involved in the UPR of CCC, and inhibiting AGR2 further enhances the UPR and confers platinum sensitivity, making it a potential therapeutic target.

Year:

2025

AGR2-high CCC organoids are sensitive to bortezomib, and AGR2 knockout reduces tumor growth. A, Heatmap showing the IC 50 of drugs selected through the HTDS of 361 compounds ( Fig. 2 ) of nine organoids (18-015, 19-079, 19-055, 19-076, 18-148, 19-042, 19-001, 19-010, and 19-044). High, green; low, magenta. B, Genes shared in at least two of the UPR-related pathways (GOBP_IRE1_mediated_unfolded_protein_response, GOBP_regulation_of_PERK_mediated_unfolded_protein_response, and GOBP_ATF6_mediated_unfolded_protein_response). AGR2 was significantly downregulated in the bortezomib-resistant 18-015 CCC organoid ( P = 0.0049). C, Read count of AGR2 in RNA sequencing of bortezomib-resistant (18-015) and other CCC organoids. D, Immunoblot analysis of UPR-related genes, including AGR2 in bortezomib-resistant (18-015) and other CCC organoids (19-001, 19-042, 19-055, 19-076, and 19-079). E, Immunoblot analysis of AGR2 -KO CCC organoid (19-042) confirmed knockout of AGR2. F, AGR2 -KO organoids exhibited significantly slower growth than the control ( P = 0.014). G, Cell cycle analysis of the AGR2 -KO CCC organoid (19-042) showed a significant increase in the G 2 –M fraction compared with the control ( P = 0.028).

Year:

2025

Box plot showing Single-sample Gene Set Enrichment Analysis (ssGSEA) scores significantly different between AGR2-knockout organoids and controls (HALLMARK_WNT_BETA_CATENIN_SIGNALING, HALLMARK_P53_PATHWAY, HALLMARK_PEROXISOME, HALLMARK_EPITHELIAL_MESENYCHYMAL_TRANSITION, HALLMARK_NOTCH_SIGNALING, HALLMARK_COAGULATION, HALLMARK_PROTEIN_SECRETION, HALLMARK_HYPOXIA). CCC, clear cell ovarian cancer; cont., control; HGSC, high-grade serous ovarian cancer

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2020

Year:

2020

Collaborators (14)

Akihito Tsuji

-

JAPAN
View details

Takashi Kamatani

Project Assistant Professor

University of Tokyo

JAPAN
View details

Taroh Satoh

Professor

Osaka University Hospital

JAPAN
View details

Daisuke Aoki

Keio University School of Medicine

JAPAN
View details

Tadamichi Denda

Head

Kanagawa Cancer Center

JAPAN
View details

Hiroyuki Takeda

Assistant professor

St. Marianna University

JAPAN
View details

Tatsuhiko Tsunoda

Professor

University of Tokyo

JAPAN
View details

Hiroyuki Yasuda

Keio University

JAPAN
View details

Shinsuke Shibata

Professor

Niigata University

JAPAN
View details

Wataru Yamagami

Professor

Keio University

JAPAN
View details

Toshiro Sato

Keio University

JAPAN
View details

Yoshito Komatsu

Hokkaido University Hospital

JAPAN
View details

Eiji Oki

Kyushu University

JAPAN
View details

Takuma Yoshimura

Keio University

JAPAN
View details